Public Comments Closing for Medicare Drug Pricing Negotiations

As the window for public comments on the US Centers for Medicare and Medicaid Services’ (CMS’s) plan to negotiate Medicare drug prices comes to a close, Republican lawmakers and pharmaceutical companies seem to be in agreement with their complaints. A group of congress members from both the Senate and House argue that the plan will hurt patients, providers, and caregivers if implemented.

According to Politico, “MS Deputy Administrator Meena Seshamani declined to comment on whether CMS anticipates litigation over the implementation of the first-ever Medicare drug-pricing negotiations and said that the agency is obligated to keep proprietary information disclosed during negotiations confidential.”

To read more, click here.

(Source: Politico, April 14^th, 2023)